American Heart Journal
Volume 153, Issue 1 , Pages 67-73 , January 2007

Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: Markers for diabetes and cardiovascular risk?

  • Jeffrey L. Anderson, MD

      Affiliations

    • Cardiovascular Department, LDS Hospital
    • University of Utah, Salt Lake City, UT
    • Corresponding Author InformationReprint requests: Jeffrey L. Anderson, MD, LDS Hospital, Cardiovascular Department, 8th Avenue and C Street, Salt Lake City, UT 84143.
    • ,
  • John F. Carlquist, PhD

      Affiliations

    • Cardiovascular Department, LDS Hospital
    • University of Utah, Salt Lake City, UT
    • ,
  • William L. Roberts, MD PhD

      Affiliations

    • University of Utah, Salt Lake City, UT
    • ARUP Laboratories, Salt Lake City, UT
    • ,
  • Benjamin D. Horne, PhD, MPH

      Affiliations

    • Cardiovascular Department, LDS Hospital
    • ,
  • Heidi T. May, MSPH

      Affiliations

    • Cardiovascular Department, LDS Hospital
    • ,
  • Elisabeth L. Schwarz

      Affiliations

    • ARUP Laboratories, Salt Lake City, UT
    • ,
  • Marzia Pasquali, PhD

      Affiliations

    • University of Utah, Salt Lake City, UT
    • ARUP Laboratories, Salt Lake City, UT
    • ,
  • Rebecca Nielson

      Affiliations

    • ARUP Laboratories, Salt Lake City, UT
    • ,
  • Mark M. Kushnir, MS

      Affiliations

    • ARUP Laboratories, Salt Lake City, UT
    • ,
  • Alan L. Rockwood, PhD

      Affiliations

    • ARUP Laboratories, Salt Lake City, UT
    • ,
  • Tami L. Bair, BS

      Affiliations

    • Cardiovascular Department, LDS Hospital
    • ,
  • Joseph B. Muhlestein, MD

      Affiliations

    • Cardiovascular Department, LDS Hospital
    • University of Utah, Salt Lake City, UT
    • ,
  • for the Intermountain Heart Collaborative (IHC) Study Group

Received 20 July 2006 ,Accepted 9 October 2006.

References 

  1. American Diabetes Association . In: Diabetes vital statistics 1996. 1996;p. 4;[Alexandria, VA]
  2. American Diabetes Association . Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183–1197
  3. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA. 1979;241:2035–2038
  4. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  5. Folsom AR, Szklo M, Stevens J, et al. A prospective study of coronary heart disease in relation to fasting insulin, glucose and diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care. 1997;20:935–942
  6. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  7. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283–303
  8. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of the metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  9. Eckel RH, Barouch WW, Ershow AG. Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on the Phathophysiology of Obesity-Associated Cardiovascular Disease. Circulation. 2002;105:2923–2928
  10. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696–2698
  11. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  12. Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes Care. 1992;41:715–722
  13. de Vegt F, Dekker J, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA. 2001;285:2109–2113
  14. Trevisan M, Liu J, Bahsas FB, et al. Syndrome X and mortality: a population-based study. Am J Epidemiol. 1998;148:958–966
  15. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  16. Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  17. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003;107:391–397
  18. Anderson JL, Horne B, Reyna S, et al. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?. Cardiology. 2004;101:185–193
  19. Mensah GA, Mokdad AH, Ford E, et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin. 2004;22:485–504
  20. Taylor GS, Muhlestein JB, Wagner GS, et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J. 1998;136:792–803
  21. Pearson TA, Mensah G, Alexander W, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  22. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240
  23. Fisman EZ, Motro M, Tenenbaum A, et al. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J. 2001;141:485–490
  24. Hoogwerf BJ, Sprecher DL, Pearce GL, et al. Fasting blood glucose in the nondiabetic range is a continuous and graded risk factor for CHD. J Am Coll Cardiol. 2002;39:221
  25. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet. 1996;347:949–950
  26. Gerstein HC. Is glucose a continuous risk factor for cardiovascular mortality. Diabetes Care. 1999;22:659–660
  27. Hsieh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med. 1998;105:4S–14S
  28. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol. 1999;84:11J–14J
  29. Smiley T, Oh P, Shane LG. The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes: a systematic review. Can J Cardiol. 2001;17:797–805
  30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  31. Wingard DL, Barrett-Connor E, Ferrara A. Is insulin really a heart disease risk factor?. Diabetes Care. 1995;18:1299–1304
  32. Jiang X, Srinivasan SR, Berenson GS. Relation of obesity to insulin secretion and clearance in adolescents: the Bogalusa Heart Study. Int J Obes Relat Metab Disord. 1996;20:951–956
  33. Relimpio F, Losada F, Pumar A, et al. Relationships of C-peptide levels and the C-peptide/bloodsugar ratio with clinical/biochemical variables associated with insulin resistance in orally-treated, well-controlled type 2 diabetic patients. Diabetes Res Clin Pract. 1997;36:173–180
  34. Wahren J, Johansson BL, Wallberg-Henriksson H, et al. C-peptide revisited-new physiological effects and therapeutic implications. J Intern Med. 1996;240:115–124
  35. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet. 2001;358:2096–2097
  36. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127–2128
  37. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420–1426
  38. Zoccali C, Bode-Boger SM, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease. Lancet. 2001;348:2113–2117
  39. Homma M, Tanaka A, Hino K, et al. Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and in patients with diabetes mellitus and chronic renal failure. Metabolism. 2001;50:801–804
  40. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–2170
  41. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2005;291:1730–1737

 This study was funded by a generous grant from the Deseret Foundation, Salt Lake City, UT.

PII: S0002-8703(06)00907-0

doi: 10.1016/j.ahj.2006.10.014

American Heart Journal
Volume 153, Issue 1 , Pages 67-73 , January 2007

Article Tools

* Image Usage & Resolution